 The Ebola outbreak was an unprecedented outbreak and a very huge crisis in West Africa, killing more than 11,000 people and making the situation very worse, impacting the socioeconomic situation in the three most affected countries like Guinea, Liberia and Sierra Leone. There was a vaccine at the early stage, in animal stage, but there was not tested at the human stage that the reason we started testing this vaccine as a clinical trial on the field with some little patient, voluntary patient, in phase one clinical trial and then moved to phase two clinical trial, about 100 and 200 cases. Our research took the opportunity to test the vaccine during this epidemics. It was a consortium composed by Canada, MSF, WHO, Wellcome Trust and among other who was involved in this clinical trial and that clinical trial was very informative because it was the unique occasion to test this vaccine during the epidemics. Our research found that the vaccine can stop an outbreak. When people heard that there was available vaccine, everybody would like to be vaccinated, but the most cost-effective strategy was to vaccinate around the at-risk population like Ebola positive cases, contacts and contact of contact. That is more cost-effective strategy as we did with WHO during the 1980s for smallpox eradication.